GLP-1受体激动剂联合孕激素治疗对子宫内膜上皮内瘤变和子宫内膜癌保留生育功能管理的影响
本研究基于美国TriNetX数据库,纳入≤45岁诊断为EIN或EC并接受保留生育功能治疗的患者,比较GLP-1RA联合孕激素与单用孕激素的子宫切除风险。经1:1倾向评分匹配后每组432例,18个月时联合组子宫切除率为10.2%,单用孕激素组为23.4%(HR 0.41,95%CI 0.29-0.58),6个月时即观察到显著降低。结论提示辅助GLP-1RA治疗与降低子宫切除风险相关。
要点
- 保护作用在6个月时即显现,且在各亚组中一致。
- 结果为回顾性关联,需前瞻性研究验证。
核心结论
- 在EIN和EC患者中,辅助GLP-1RA治疗与子宫切除风险降低相关。
- 该结果支持开展前瞻性保留生育功能研究。
研究设计与样本
- 回顾性队列研究,使用TriNetX研究协作网络(2017年1月1日至2025年12月1日)。
- 纳入≤45岁诊断为EIN或EC并启动保留生育功能治疗的患者。
- 比较GLP-1RA联合孕激素组与单用孕激素组,经1:1倾向评分匹配后每组432例。
- 随访6、12、18个月,主要结局为子宫切除,采用Cox比例风险回归估计HR。
主要发现
- 18个月时,GLP-1RA联合孕激素组子宫切除率为10.2%,单用孕激素组为23.4%(HR 0.41,95%CI 0.29-0.58)。
- 6个月时即观察到子宫切除风险显著降低。
- 保护关联在<40岁、EC诊断、孕激素类型(LNG-IUD或口服孕激素)和GLP-1RA类型(司美格鲁肽或替尔泊肽)亚组中一致。
临床怎么用
- 对于接受保留生育功能治疗的EIN或EC患者,可考虑在孕激素基础上加用GLP-1RA以降低子宫切除风险。
- 治疗决策需结合患者个体情况,并告知当前证据为回顾性关联。
局限性
- 回顾性研究设计,可能存在未测量混杂。
- 数据来源于美国数据库,外推需谨慎。
- 缺乏前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We examined whether the addition of GLP-1RA to progestin therapy reduced the risk of hysterectomy in patients with endometrial intraepithelial neoplasia (EIN) and endometrial cancer (EC) in the U.S. managed with fertility-sparing management. METHODS: Women ≤45 years old at EIN/EC diagnosis were identified in the TriNetX Research Collaborative Network (1/1/2017-12/01/2025). Patients initiating GLP-1 RA plus progestins (megestrol acetate, medroxyprogesterone acetate, or levonorgestrel-releasing intrauterine device) formed the GLP-1 RA + progestin group and were compared with the progestin-only group. Groups were 1:1 propensity-score matched (PSM) for demographics, BMI, HbA1c, type 2 diabetes, comorbidities, medication use, healthcare utilization, and EIN/EC. Patients were followed up for 6, 12, and 18 months from treatment initiation until the occurrence of hysterectomy; loss to follow-up; or December 1, 2025. Hazard ratios (HRs) with 95% confidence intervals (CI) were estimated using Cox proportional hazards regression. Analyses for subgroups, head-to-head comparisons were also performed. RESULTS: After 1:1 PSM (n = 432 in each group), hysterectomy occurred in 10.2% of the GLP-1RA + progestin group versus 23.4% in the matched progestin-only group (HR 0.41, 95% CI 0.29-0.58) at 18 months, with significant reductions observed as early as 6 months. This protective association was consistent across subgroups, including younger patients (<40 years), EC diagnosis, progestin type (LNG-IUD or oral progestins), and GLP-1RA type (semaglutide or tirzepatide). CONCLUSION: Adjunct GLP-1 receptor agonist therapy was associated with reduced hysterectomy risk in EIN and EC, supporting prospective fertility-sparing studies.
引用
- Hsieh TYJ, Yen TT, Hacker MR, et al. Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer. Gynecol Oncol. 2026. PMID: 42000371. doi:10.1016/j.ygyno.2026.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。